Drugs

FDA approves Targiniq ER with abuse-deterrent properties

[7/23/2014] FDA has approved Targiniq ER, a new extended-release pain reliever that contains a combination of oxycodone and naloxone. Targiniq ER is the second extended-release/long-acting (ER/LA) opioid analgesic with FDA-approved labeling describing the product’s properties that are expected to reduce, but not totally prevent, abuse by snorting or injecting.  


July 23, 2014

Related Information

 

Page Last Updated: 07/24/2014
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.